Payment overview · 2025
General Payments
$1,259.39
85 reported records · 11 companies
Healthcare provider profile · identity verified
Leslye Mcgrath, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PARAGOULD, AR · NPI 1326245291
Verified facts
What the public records show
CMS Open Payments records show Leslye Mcgrath, M.D. received $1,259.39 in general payments during 2025 across 85 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Nurtec Odt, Ozempic, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $320.97 | 25.5% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $229.76 | 18.2% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $197.48 | 15.7% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $166.52 | 13.2% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $150.34 | 11.9% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $69.40 | 5.5% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.96 | 3.2% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.05 | 2.5% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $21.29 | 1.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.04 | 1.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.58 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,259.39 | 85 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $211.75 | 17 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $202.37 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $176.56 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $163.88 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $155.90 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $154.51 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $120.53 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $120.50 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $117.39 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $117.39 | 9 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $71.89 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $69.40 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $66.16 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.26 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $40.96 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $32.95 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $31.05 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $12.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 216 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 11 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
216 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
216 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 511 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 504 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 435 | 86 |
| Potassium Chloride | Potassium Chloride | 344 | 51 |
| Omeprazole | Omeprazole | 324 | 66 |
| Gabapentin | Gabapentin | 322 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 63 |
| Lisinopril | Lisinopril | 307 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 286 | 53 |
| Losartan Potassium | Losartan Potassium | 255 | 53 |
| Furosemide | Furosemide | 248 | 57 |
| Alprazolam | Alprazolam | 245 | 40 |
| Trazodone Hcl | Trazodone Hcl | 222 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 221 | 37 |
| Eliquis | Apixaban | 216 | 23 |
| Simvastatin | Simvastatin | 208 | 46 |
| Tramadol Hcl | Tramadol Hcl | 193 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 36 |
| Famotidine | Famotidine | 192 | 35 |
| Metformin Hcl | Metformin Hcl | 192 | 41 |
| Donepezil Hcl | Donepezil Hcl | 173 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 149 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 28 |
| Lorazepam | Lorazepam | 143 | 42 |
| Clonazepam | Clonazepam | 142 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 32 |
| Memantine Hcl | Memantine Hcl | 139 | 21 |
| Meloxicam | Meloxicam | 138 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 42 |
| Mirtazapine | Mirtazapine | 129 | 18 |
| Ezetimibe | Ezetimibe | 125 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 25 |
| Sertraline Hcl | Sertraline Hcl | 106 | 28 |
| Glipizide | Glipizide | 105 | 24 |
| Buspirone Hcl | Buspirone Hcl | 102 | 18 |
| Prednisone | Prednisone | 101 | 83 |
| Jardiance | Empagliflozin | 97 | 17 |
| Montelukast Sodium | Montelukast Sodium | 94 | 19 |
| Spironolactone | Spironolactone | 93 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 78 | 14 |
| Pregabalin | Pregabalin | 77 | 16 |
| Xarelto | Rivaroxaban | 77 | suppressed |
| Ozempic | Semaglutide | 75 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 13 |
| Alendronate Sodium | Alendronate Sodium | 69 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 62 |
| Myrbetriq | Mirabegron | 67 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 54 |
| Amiodarone Hcl | Amiodarone Hcl | 65 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 65 | 11 |
| Ondansetron Odt | Ondansetron | 65 | 32 |
| Cefdinir | Cefdinir | 60 | 51 |
| Allopurinol | Allopurinol | 59 | 13 |
| Lovastatin | Lovastatin | 59 | suppressed |
| Glipizide Er | Glipizide | 57 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 13 |
| Carvedilol | Carvedilol | 55 | 12 |
| Farxiga | Dapagliflozin Propanediol | 51 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 50 | suppressed |
| Primidone | Primidone | 47 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Cephalexin | Cephalexin | 41 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 14 |
| Finasteride | Finasteride | 39 | suppressed |
| Sotalol | Sotalol Hcl | 39 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Topiramate | Topiramate | 31 | 11 |
| Nystatin | Nystatin | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 11 |
| Azithromycin | Azithromycin | 29 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Premarin | Estrogens, Conjugated | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 25 |
| Nitroglycerin | Nitroglycerin | 28 | 17 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 26 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 24 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 24 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 21 |
| Diazepam | Diazepam | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 12 |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Ivermectin | Ivermectin | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Sulindac | Sulindac | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,259.39 · 85 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, ELIQUIS, FARXIGA, KISUNLA, MOUNJARO, NUPLAZID, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error